Triage Plus was designed to detect mRNAs and DNA single-nucleotide variants from fibroblast growth factor receptor 3 and telomerase reverse transcriptase genes associated with bladder cancer.

Background: Bladder cancer is a disease with complex perturbations in gene networks and heterogeneous in terms of histology, mutations, and prognosis. Advances in high-throughput sequencing technologies, genome-wide association studies, and bioinformatics methods have revealed greater insights into the pathogenesis of complex diseases. Network biology-based approaches have been used to demonstrate the complex physical or functional interactions between molecules which can lead to potential drug targets. Objective: There is a need to better understand gene networks and protein-protein interactions (PPI) specific to urothelial carcinoma. Methods: We performed a multi-sample PPI study comparing two urothelial carcinoma architectures: papillary and non-papillary. We used a novel PPI analysis tool, Proteinarium to identify clusters of patients with shared PPI networks in each architecture. The feature of this tool is to analyze the PPI networks of patients and visualize them in clusters based on their network similarities from any genomic data including Next Generation Sequencing (NGS). Results: We observed distinct networks for the papillary and non-papillary groups. Proteins unique to the papillary urothelial carcinoma detected in two separate datasets included UBA52, RPS27A, UBR4, CUL1, UBE2K, and CDC5L. Proteins found in the non-papillary urothelial carcinoma specific PPI network were GNB1, UBC, RHOA, FPR2, GNGT1, PIK3CA, PIK3CG, HSP90AA1, SLC11A1, CCT7, ARHGEF1, PAK1, PAK2, PSMA7, and TRIO. Conclusions: We identified distinct PPI networks specific to papillary and non-papillary urothelial carcinomas presenting unique molecular entities. Clinical Trial: N/A

Izalontamab brengitecan showed signals of activity in patients with pretreated locally advanced or metastatic urothelial carcinoma.

“To our knowledge, the SOGUG-AUREA trial showed, for the first time, that the combination of atezolizumab with split doses of cisplatin and gemcitabine was effective and safe for patients with mUC ,” the researchers wrote.

“The prognostic value of early on-treatment weight loss was independent of prognostic factors previously identified for platinum-based chemotherapy, such as age, baseline albumin, renal function, and ECOG performance status,” the researchers wrote.

“To our knowledge, the SOGUG-AUREA trial showed, for the first time, that the combination of atezolizumab with split doses of cisplatin and gemcitabine was effective and safe for patients with mUC ,” the researchers wrote.

“The prognostic value of early on-treatment weight loss was independent of prognostic factors previously identified for platinum-based chemotherapy, such as age, baseline albumin, renal function, and ECOG performance status,” the researchers wrote.

Ashish Kamat: Molecular Profiling of 99 Cases of Micropapillary Urothelial Carcinoma / Arlene Siefker-Radtke, Ashish Kamat, Ashish M. Kamat, Bogdan Czerniak,

Tian Zhang: Best practices for second line treatment in Metastatic Urothelial Carcinoma / Astellas, atezolizumab, Aveluma, Avelumab, Biomarker selection,

Loss of Kmt2c or Kmt2d in mice drives the redeployment of KMT2A–menin to bivalent promoters, leading to changes in gene expression. This primes cells for transformation and elicits sensitivity to EGFR...

Petros Grivas: TROPiCS04 P3 trial data has been published / A. Necchi, C. Vulsteke, C.N. Sternberg, C.S. Sima, cancer, F. Boateng, I. Durán, J. Bellmunt, J.

Advancements in urothelial carcinoma treatment - International Urology Cancer Summit / Abhishek Tripathi, Alan Tan, Andrea Apolo, cancer, Daniel Petrylak,

Five articles suggested by Yüksel Ürün / Ankara University School of Medicine, BRCA, cancer, Charlie A. Hamm, CLEAR, Elizabeth J.Schafer, fight against